Login Register Cart 0
Generic placeholder image

Current Neuropharmacology

Editor-in-Chief

ISSN (Print): 1570-159X
ISSN (Online): 1875-6190

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Sex Differences in Serum Prolactin Levels in Children and Adolescents on Antipsychotics: A Systematic Review and Meta-Analysis

Author(s): Lidia Ilzarbe, Daniel Ilzarbe, Felipe Gutiérrez-Arango and Inmaculada Baeza*

Volume 21, Issue 6, 2023

Published on: 31 October, 2022

Page: [1319 - 1328] Pages: 10

DOI: 10.2174/1570159X21666221027143920

Price: $65

Abstract

Background: Serum prolactin levels are influenced by sex, physical development and medications among other factors. Antipsychotics usually increase serum prolactin levels in both adults and younger patients, but no study has reviewed the potential association between sex and vulnerability for developing hyperprolactinemia among children and adolescents.

Objective: Systematic review and meta-analysis of serum prolactin levels in children and adolescents on antipsychotic treatment for any psychiatric diagnosis to determine the effect of sex.

Methods: A systematic search was performed in MEDLINE/PubMed/Web of Science and Cochrane databases for randomized controlled trials of antipsychotics in children and adolescents reporting serum prolactin levels by sex.

Results: Of 1278 identified records, seven studies were included, comparing different single antipsychotics to placebo (risperidone N=4; lurasidone N=1; olanzapine N=1; queriapine N=1). Both male and female children and adolescents on antipsychotics presented a significant increase in prolactin levels relative to subjects receiving a placebo. (Male: 16.53 with 95% CI: 6.15-26.92; Female: 26.97 with 95% CI: 9.18-44.75). The four studies using risperidone had similar findings (Male: 26.49 with 95% CI: 17.55-35.43; Female: 37.72 with 95% CI: 9.41-66.03). In the direct comparison between sexes, females showed greater increases in prolactin, but the differences were not statistically significant.

Conclusion: Serum prolactin levels are increased in children and adolescents of both sexes on antipsychotics, with females showing a slightly greater increase than males. Further research is needed to clarify the influence of sex and pubertal status on prolactin levels in children and adolescents taking antipsychotics.

« Previous Next »
Graphical Abstract

[1]
Roelfsema, F.; Pijl, H.; Keenan, D.M.; Veldhuis, J.D. Prolactin secretion in healthy adults is determined by gender, age and body mass index. PLoS One, 2012, 7(2), e31305.
[http://dx.doi.org/10.1371/journal.pone.0031305] [PMID: 22363612]
[2]
Alosaimi, F.D.; Fallata, E.O.; Abalhassan, M.; Alhabbad, A.; Alzain, N.; Alhaddad, B.; Alassiry, M.Z. Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications. Int. J. Psychiatry Clin. Pract., 2018, 22(4), 274-281.
[http://dx.doi.org/10.1080/13651501.2018.1425459] [PMID: 29334291]
[3]
Fitzgerald, P.; Dinan, T.G. Prolactin and dopamine: What is the connection? A review article. J. Psychopharmacol., 2008, 22(2_suppl)(Suppl.), 12-19.
[http://dx.doi.org/10.1177/0269216307087148] [PMID: 18477617]
[4]
Bostwick, J.R.; Guthrie, S.K.; Ellingrod, V.L. Antipsychotic-induced hyperprolactinemia. Pharmacotherapy, 2009, 29(1), 64-73.
[http://dx.doi.org/10.1592/phco.29.1.64] [PMID: 19113797]
[5]
Balijepalli, C.; Druyts, E.; Zoratti, M.J.; Wu, P.; Kanji, S.; Rabheru, K.; Yan, K.; Thorlund, K. Change in prolactin levels in pediatric patients given antipsychotics for schizophrenia and schizophrenia spectrum disorders: A network meta-analysis. Schizophr. Res. Treatment, 2018, 2018, 1-9.
[http://dx.doi.org/10.1155/2018/1543034] [PMID: 29805808]
[6]
Peuskens, J.; Pani, L.; Detraux, J.; De Hert, M. The effects of novel and newly approved antipsychotics on serum prolactin levels: A comprehensive review. CNS Drugs, 2014, 28(5), 421-453.
[http://dx.doi.org/10.1007/s40263-014-0157-3] [PMID: 24677189]
[7]
Kinon, B.J.; Gilmore, J.A.; Liu, H.; Halbreich, U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone11This work was sponsored by Eli Lilly and Company. Psychoneuroendocrinology, 2003, 28(Suppl. 2), 55-68.
[http://dx.doi.org/10.1016/S0306-4530(02)00127-0] [PMID: 12650681]
[8]
Gopal, S.; Lane, R.; Nuamah, I.; Copenhaver, M.; Singh, J.; Hough, D.; Bach, M.; Savitz, A. Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone Extended-Release (ER) for 2 years: A post hoc analysis of an open-label multicenter study. CNS Drugs, 2017, 31(9), 797-808.
[http://dx.doi.org/10.1007/s40263-017-0437-9] [PMID: 28660406]
[9]
Emmanuel, M.; Bokor, B.R. Tanner Stages: In Treasure Island, FL, 2022.
[10]
Elmlinger, M.W.; Kühnel, W.; Ranke, M.B. Reference ranges for serum concentrations of lutropin (LH), follitropin (FSH), estradiol (E2), prolactin, progesterone, sex hormone-binding globulin (SHBG), dehydroepiandrosterone sulfate (DHEAS), cortisol and ferritin in neonates, children and young adults. Clin. Chem. Lab. Med., 2002, 40(11), 1151-1160.
[http://dx.doi.org/10.1515/cclm.2002.202] [PMID: 12521235]
[11]
Aldrimer, M.; Ridefelt, P.; Rödöö, P.; Niklasson, F.; Gustafsson, J.; Hellberg, D. Reference intervals on the Abbot Architect for serum thyroid hormones, lipids and prolactin in healthy children in a population-based study. Scand. J. Clin. Lab. Invest., 2012, 72(4), 326-332.
[http://dx.doi.org/10.3109/00365513.2012.667571] [PMID: 22724627]
[12]
Molitch, M.E. Medication-Induced Hyperprolactinemia. Mayo Clin. Proc., 2005, 80(8), 1050-1057.
[http://dx.doi.org/10.4065/80.8.1050] [PMID: 16092584]
[13]
Lally, J.; Ajnakina, O.; Stubbs, B.; Williams, H.R.; Colizzi, M.; Carra, E.; Fraietta, S.; Gardner-Sood, P.; Greenwood, K.E.; Atakan, Z.; Mondelli, V.; Ismail, K.; Howes, O.; Taylor, D.M.; Smith, S.; Hopkins, D.; Murray, R.M.; Gaughran, F. Hyperprolactinaemia in first episode psychosis - A longitudinal assessment. Schizophr. Res., 2017, 189, 117-125.
[http://dx.doi.org/10.1016/j.schres.2017.07.037] [PMID: 28755878]
[14]
DelBello, M.P.; Kadakia, A.; Heller, V.; Singh, R.; Hagi, K.; Nosaka, T.; Loebel, A. Systematic review and network meta-analysis: Efficacy and safety of second-generation antipsychotics in youths with bipolar depression. J. Am. Acad. Child Adolesc. Psychiatry, 2022, 61(2), 243-254.
[http://dx.doi.org/10.1016/j.jaac.2021.03.021] [PMID: 34420839]
[15]
Krause, M.; Zhu, Y.; Huhn, M.; Schneider-Thoma, J.; Bighelli, I.; Chaimani, A.; Leucht, S. Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. Eur. Neuropsychopharmacol., 2018, 28(6), 659-674.
[http://dx.doi.org/10.1016/j.euroneuro.2018.03.008] [PMID: 29802039]
[16]
Pagsberg, A.K.; Tarp, S.; Glintborg, D.; Stenstrøm, A.D.; Fink-Jensen, A.; Correll, C.U.; Christensen, R. Acute antipsychotic treatment of children and adolescents with schizophrenia-spectrum disorders: A systematic review and network meta-analysis. J. Am. Acad. Child Adolesc. Psychiatry, 2017, 56(3), 191-202.
[http://dx.doi.org/10.1016/j.jaac.2016.12.013] [PMID: 28219485]
[17]
Riecher-Rössler, A.; Rybakowski, J.K.; Pflueger, M.O.; Beyrau, R.; Kahn, R.S.; Malik, P.; Fleischhacker, W.W. Hyperprolactinemia in antipsychotic-naive patients with first-episode psychosis. Psychol. Med., 2013, 43(12), 2571-2582.
[http://dx.doi.org/10.1017/S0033291713000226] [PMID: 23590895]
[18]
Garcia-Rizo, C.; Fernandez-Egea, E.; Oliveira, C.; Justicia, A.; Parellada, E.; Bernardo, M.; Kirkpatrick, B. Prolactin concentrations in newly diagnosed, antipsychotic-naïve patients with nonaffective psychosis. Schizophr. Res., 2012, 134(1), 16-19.
[http://dx.doi.org/10.1016/j.schres.2011.07.025] [PMID: 21831600]
[19]
Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; Chou, R.; Glanville, J.; Grimshaw, J.M.; Hróbjartsson, A.; Lalu, M.M.; Li, T.; Loder, E.W.; Mayo-Wilson, E.; McDonald, S.; McGuinness, L.A.; Stewart, L.A.; Thomas, J.; Tricco, A.C.; Welch, V.A.; Whiting, P.; Moher, D. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021, 372(71), n71.
[http://dx.doi.org/10.1136/bmj.n71] [PMID: 33782057]
[20]
Kennedy, C.E.; Fonner, V.A.; Armstrong, K.A.; Denison, J.A.; Yeh, P.T.; O’Reilly, K.R.; Sweat, M.D. The evidence project risk of bias tool: Assessing study rigor for both randomized and non-randomized intervention studies. Syst. Rev., 2019, 8(1), 3.
[http://dx.doi.org/10.1186/s13643-018-0925-0] [PMID: 30606262]
[21]
Jadad, A.R.; Moore, R.A.; Carroll, D.; Jenkinson, C.; Reynolds, D.J.M.; Gavaghan, D.J.; McQuay, H.J. Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control. Clin. Trials, 1996, 17(1), 1-12.
[http://dx.doi.org/10.1016/0197-2456(95)00134-4] [PMID: 8721797]
[22]
Leucht, S.; Samara, M.; Heres, S.; Patel, M.X.; Woods, S.W.; Davis, J.M. Dose equivalents for second-generation antipsychotics: the minimum effective dose method. Schizophr. Bull., 2014, 40(2), 314-326.
[http://dx.doi.org/10.1093/schbul/sbu001] [PMID: 24493852]
[23]
Aman, M.G.; De Smedt, G.; Derivan, A.; Lyons, B.; Findling, R.L. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry, 2002, 159(8), 1337-1346.
[http://dx.doi.org/10.1176/appi.ajp.159.8.1337] [PMID: 12153826]
[24]
Findling, R.L.; McKenna, K.; Earley, W.R.; Stankowski, J.; Pathak, S. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J. Child Adolesc. Psychopharmacol., 2012, 22(5), 327-342.
[http://dx.doi.org/10.1089/cap.2011.0092] [PMID: 23083020]
[25]
Goldman, R.; Loebel, A.; Cucchiaro, J.; Deng, L.; Findling, R.L. Efficacy and safety of lurasidone in adolescents with schizophrenia: A 6-week, randomized placebo-controlled study. J. Child Adolesc. Psychopharmacol., 2017, 27(6), 516-525.
[http://dx.doi.org/10.1089/cap.2016.0189] [PMID: 28475373]
[26]
Haas, M.; DelBello, M.P.; Pandina, G.; Kushner, S.; Van Hove, I.; Augustyns, I.; Quiroz, J.; Kusumakar, V. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disord., 2009, 11(7), 687-700.
[http://dx.doi.org/10.1111/j.1399-5618.2009.00750.x] [PMID: 19839994]
[27]
Haas, M.; Unis, A.S.; Armenteros, J.; Copenhaver, M.D.; Quiroz, J.A.; Kushner, S.F. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia. J. Child Adolesc. Psychopharmacol., 2009, 19(6), 611-621.
[http://dx.doi.org/10.1089/cap.2008.0144] [PMID: 20035579]
[28]
Snyder, R.; Turgay, A.; Aman, M.; Binder, C.; Fisman, S.; Carroll, A. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs. J. Am. Acad. Child Adolesc. Psychiatry, 2002, 41(9), 1026-1036.
[http://dx.doi.org/10.1097/00004583-200209000-00002] [PMID: 12218423]
[29]
Tohen, M.; Kryzhanovskaya, L.; Carlson, G.; DelBello, M.; Wozniak, J.; Kowatch, R.; Wagner, K.; Findling, R.; Lin, D.; Robertson-Plouch, C.; Xu, W.; Dittmann, R.W.; Biederman, J. Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am. J. Psychiatry, 2007, 164(10), 1547-1556.
[http://dx.doi.org/10.1176/appi.ajp.2007.06111932] [PMID: 17898346]
[30]
Kryzhanovskaya, L.; Schulz, S.C.; Mcdougle, C.; Frazier, J.; Dittmann, R.; Robertson-Plouch, C.; Bauer, T.; Xu, W.; Wang, W.; Carlson, J.; Tohen, M. Olanzapine versus placebo in adolescents with schizophrenia: A 6-week, randomized, double-blind, placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry, 2009, 48(1), 60-70.
[http://dx.doi.org/10.1097/CHI.0b013e3181900404] [PMID: 19057413]
[31]
Kowatch, R.A.; Scheffer, R.E.; Monroe, E.; Delgado, S.; Altaye, M.; Lagory, D. Placebo-controlled trial of valproic Acid versus risperidone in children 3-7 years of age with bipolar I disorder. J. Child Adolesc. Psychopharmacol., 2015, 25(4), 306-313.
[http://dx.doi.org/10.1089/cap.2014.0166] [PMID: 25978742]
[32]
Singh, J.; Robb, A.; Vijapurkar, U.; Nuamah, I.; Hough, D. A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol. Psychiatry, 2011, 70(12), 1179-1187.
[http://dx.doi.org/10.1016/j.biopsych.2011.06.021] [PMID: 21831359]
[33]
Saito, E.; Correll, C.U.; Gallelli, K.; McMeniman, M.; Parikh, U.H.; Malhotra, A.K.; Kafantaris, V. A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J. Child Adolesc. Psychopharmacol., 2004, 14(3), 350-358.
[http://dx.doi.org/10.1089/cap.2004.14.350] [PMID: 15650492]
[34]
Alfaro, C.L.; Wudarsky, M.; Nicolson, R.; Gochman, P.; Sporn, A.; Lenane, M.; Rapoport, J.L. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J. Child Adolesc. Psychopharmacol., 2002, 12(2), 83-91.
[http://dx.doi.org/10.1089/104454602760219126] [PMID: 12188977]
[35]
Alonso, L.C.; Rosenfield, R.L. Oestrogens and puberty. Best Pract. Res. Clin. Endocrinol. Metab., 2002, 16(1), 13-30.
[http://dx.doi.org/10.1053/beem.2002.0177] [PMID: 11987895]
[36]
Koskas, T.; Souaré, K.; Ouahabi, T.; Porquet, D.; Chevenne, D. Reference intervals for follicle-stimulating hormone, luteinizing hormone and prolactin in children and young adults on the bioMérieux Mini-Vidas system. Clin. Chem. Lab. Med., 2007, 45(4), 541-545.
[http://dx.doi.org/10.1515/CCLM.2007.086] [PMID: 17439335]
[37]
Chan, M.K.; Seiden-Long, I.; Aytekin, M.; Quinn, F.; Ravalico, T.; Ambruster, D.; Adeli, K. Canadian Laboratory Initiative on Pediatric Reference Interval Database (CALIPER): Pediatric reference intervals for an integrated clinical chemistry and immunoassay analyzer, Abbott ARCHITECT ci8200. Clin. Biochem., 2009, 42(9), 885-891.
[http://dx.doi.org/10.1016/j.clinbiochem.2009.01.014] [PMID: 19318027]
[38]
Soldin, S.J.; Morales, A.; Albalos, F.; Lenherr, S.; Rifai, N. Pediatric reference ranges on the Abbott IMx for FSH, LH, prolactin, TSH, T4, T3, freeT4, freeT3, T-uptake, IgE, and ferritin. Clin. Biochem., 1995, 28(6), 603-606.
[http://dx.doi.org/10.1016/0009-9120(95)00038-5] [PMID: 8595709]
[39]
Anderson, G.M.; Scahill, L.; McCracken, J.T.; McDougle, C.J.; Aman, M.G.; Tierney, E.; Arnold, L.E.; Martin, A.; Katsovich, L.; Posey, D.J.; Shah, B.; Vitiello, B. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol. Psychiatry, 2007, 61(4), 545-550.
[http://dx.doi.org/10.1016/j.biopsych.2006.02.032] [PMID: 16730335]
[40]
Findling, R.L.; Johnson, J.L.; McClellan, J.; Frazier, J.A.; Vitiello, B.; Hamer, R.M.; Lieberman, J.A.; Ritz, L.; McNamara, N.K.; Lingler, J.; Hlastala, S.; Pierson, L.; Puglia, M.; Maloney, A.E.; Kaufman, E.M.; Noyes, N.; Sikich, L. Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J. Am. Acad. Child Adolesc. Psychiatry, 2010, 49(6), 583-594.
[PMID: 20494268]
[41]
Sikich, L.; Frazier, J.A.; McClellan, J.; Findling, R.L.; Vitiello, B.; Ritz, L.; Ambler, D.; Puglia, M.; Maloney, A.E.; Michael, E.; De Jong, S.; Slifka, K.; Noyes, N.; Hlastala, S.; Pierson, L.; McNamara, N.K.; Delporto-Bedoya, D.; Anderson, R.; Hamer, R.M.; Lieberman, J.A. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am. J. Psychiatry, 2008, 165(11), 1420-1431.
[http://dx.doi.org/10.1176/appi.ajp.2008.08050756] [PMID: 18794207]
[42]
Crawford, A.M.K.; Beasley, C.M., Jr; Tollefson, G.D. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr. Res., 1997, 26(1), 41-54.
[http://dx.doi.org/10.1016/S0920-9964(97)00036-4] [PMID: 9376336]
[43]
Kent, J.M.; Kushner, S.; Ning, X.; Karcher, K.; Ness, S.; Aman, M.; Singh, J.; Hough, D. Risperidone dosing in children and adolescents with autistic disorder: A double-blind, placebo-controlled study. J. Autism Dev. Disord., 2013, 43(8), 1773-1783.
[http://dx.doi.org/10.1007/s10803-012-1723-5] [PMID: 23212807]
[44]
Masi, G.; Milone, A.; Stawinoga, A.; Veltri, S.; Pisano, S. Efficacy and safety of risperidone and quetiapine in adolescents with bipolar II disorder comorbid with conduct disorder. J. Clin. Psychopharmacol., 2015, 35(5), 587-590.
[http://dx.doi.org/10.1097/JCP.0000000000000371] [PMID: 26226481]
[45]
Swadi, H.S.; Craig, B.J.; Pirwani, N.Z.; Black, V.C.; Buchan, J.C.; Bobier, C.M. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. Int. Clin. Psychopharmacol., 2010, 25(1), 1-6.
[http://dx.doi.org/10.1097/YIC.0b013e3283320511] [PMID: 19809337]
[46]
Lamberti, M.; Siracusano, R.; Italiano, D.; Alosi, N.; Cucinotta, F.; Di Rosa, G.; Germanò, E.; Spina, E.; Gagliano, A. Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD: A pilot, open-label, randomized controlled study. Paediatr. Drugs, 2016, 18(4), 319-329.
[http://dx.doi.org/10.1007/s40272-016-0183-3] [PMID: 27278054]
[47]
Haas, M.; Eerdekens, M.; Kushner, S.; Singer, J.; Augustyns, I.; Quiroz, J.; Pandina, G.; Kusumakar, V. Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: Double-blind study. Br. J. Psychiatry, 2009, 194(2), 158-164.
[http://dx.doi.org/10.1192/bjp.bp.107.046177] [PMID: 19182179]
[48]
Findling, R.L.; Landbloom, R.P.; Mackle, M.; Pallozzi, W.; Braat, S.; Hundt, C.; Wamboldt, M.Z.; Mathews, M. Safety and efficacy from an 8 week double-blind trial and a 26 week open-label extension of asenapine in adolescents with schizophrenia. J. Child Adolesc. Psychopharmacol., 2015, 25(5), 384-396.
[http://dx.doi.org/10.1089/cap.2015.0027] [PMID: 26091193]
[49]
Findling, R.L.; Robb, A.; Nyilas, M.; Forbes, R.A.; Jin, N.; Ivanova, S.; Marcus, R.; McQuade, R.D.; Iwamoto, T.; Carson, W.H. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am. J. Psychiatry, 2008, 165(11), 1432-1441.
[http://dx.doi.org/10.1176/appi.ajp.2008.07061035] [PMID: 18765484]
[50]
Akula, N.; Baranova, A.; Seto, D.; Solka, J.; Nalls, M.A.; Singleton, A.; Ferrucci, L.; Tanaka, T.; Bandinelli, S.; Cho, Y.S.; Kim, Y.J.; Lee, J.Y.; Han, B.G.; McMahon, F.J. A network-based approach to prioritize results from genome-wide association studies. PLoS One, 2011, 6(9), e24220.
[http://dx.doi.org/10.1371/journal.pone.0024220] [PMID: 21915301]
[51]
Kapur, S.; Seeman, P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci., 2000, 25(2), 161-166.
[PMID: 10740989]
[52]
Seeman, P.; Tallerico, T. Rapid release of antipsychotic drugs from dopamine D2 receptors: An explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry, 1999, 156(6), 876-884.
[http://dx.doi.org/10.1176/ajp.156.6.876] [PMID: 10360126]
[53]
Seeman, P.; Tallerico, T. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol. Psychiatry, 1998, 3(2), 123-134.
[http://dx.doi.org/10.1038/sj.mp.4000336] [PMID: 9577836]
[54]
Aringhieri, S.; Carli, M.; Kolachalam, S.; Verdesca, V.; Cini, E.; Rossi, M.; McCormick, P.J.; Corsini, G.U.; Maggio, R.; Scarselli, M. Molecular targets of atypical antipsychotics: From mechanism of action to clinical differences. Pharmacol. Ther., 2018, 192, 20-41.
[http://dx.doi.org/10.1016/j.pharmthera.2018.06.012] [PMID: 29953902]
[55]
Carli, M.; Kolachalam, S.; Longoni, B.; Pintaudi, A.; Baldini, M.; Aringhieri, S.; Fasciani, I.; Annibale, P.; Maggio, R.; Scarselli, M. Atypical antipsychotics and metabolic syndrome: From molecular mechanisms to clinical differences. Pharmaceuticals (Basel), 2021, 14(3), 238.
[http://dx.doi.org/10.3390/ph14030238] [PMID: 33800403]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy